CBT-009

Myopia, also known as near-sightedness, can develop and progress in children and adolescents. Myopia is believed to be caused by an increase in eye length or by a change in corneal curvature, which directs light from distant objects to focus in front of the retina leading to blurred long-distance vision. Myopia with a refractive error of 0.50 to -6.00 diopters is considered to be low to moderate in severity, while myopia exceeding -6.00 diopters is considered higher in severity. Progressive myopia can also be due to an increase in the axial length of the eyeball, which heightens the risk for retinal degenerative changes and permanent vision loss.  Myopia is a leading cause of correctable vision loss with a potential for complications that can lead to blindness. If treated early, there is a potential for preventing myopia-associated complications.

阿托品是唯一被证明 been demonstrated to be consistently effective in slowing myopic progression. Currently, aqueous atropine eye drops are used in some 阿托品水滴眼液来治疗近视患者，queous atropine eye drops are unstable and easily decompose into belladonna, 此外， 水性阿托品滴眼液不稳定，容易分解成颠茄、托品酸等物质，极大影响了这些滴眼液的功效和安全性。 

作为非水剂阿托品滴眼剂，CBT-009 与水剂阿托品不同的是， atropine by having higher stability, being preservative-free, and having higher 并且具有更高的生物利用度。